announcement, page-2

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
28 March 2014


PRIMA BIOMED’S CVAC™ DATA DEMONSTRATING IMPROVEMENT IN PFS IN SECOND
REMISSION OVARIAN CANCER ACCEPTED FOR ORAL PRESENTATION AT ASCO

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) announced
today that the American Society of Clinical Oncology has accepted the abstract entitled,
“Progression-free survival in ovarian cancer patients in second remission is improved with
mucin-1 autologous dendritic cell therapy” for oral presentation at the Gynecologic Cancer
Session at the 2014 ASCO Annual Meeting to be held May 30 – June 3, 2014 in Chicago.

Heidi Gray, MD, Associate Professor, Department of Obstetrics and Gynecology, University of
Washington School of Medicine, is the lead author and will deliver the oral preseentation.

Dr. Gray will present the final progression-free survival data (PFS) and an update on overall
survival (OS) from the Randomized, Open-Label Phase IIb Trial of Maintenance Therapy with a
MUC1 Dendritic Cell Vaccine (CVac™) for Epithelial Ovarian Cancer Patients in First or Second
Remission (Prima protocol CAN-003).

In accordance with ASCO policy, information in the abstract and data to be presented is
considered confidential and is embargoed until presentation at the ASCO Annual Meeting.
Prima will provide timely information on the final PFS data and updated OS data from CAN-003
after Dr. Gray’s presentation.